RESEARCH ARTICLE Open Access Tyrosine kinases inhibition

Full list of author information is available at the end of the articleBackground IgA nephropathy, a mesangial proliferative glomeruloneph-ritis, is the most common primary glomerulonephritis worldwide, and as many as 20-30 % of patients with IgA ne-phropathy progress to end-stage renal failure after 20– 25 years [1-4]. It is characterized by in the beginning phase with expansion of glomerular mesangial matrix and me-sangial cell proliferation, and a subsequent progression phase with glomerulosclerosis, tubulointerstitial fibrosis and ongoing loss in renal function, which is a hallmark of many chronic glomerulonephritis [5]. The progress from glomerulonephritis to end-stage renal disease and the need for renal replacement therapy can even be seen when the initial glomerulonephritic phase has been resolved, sug-gesting a self-perpetuated and intrarenal mechanism is ope-rating during the disease progression